A procedure for molecular identification of Burkholderia gladioli is described. Specific 16S and 23S rRNA gene signature sequences were defined as primers for PCR. The method allows rapid and specific discrimination of B. gladioli from related species (B. cepacia, B. multivorans, B. vietnamiensis, B. mallei, B. pseudomallei, Ralstonia pickettii, and R. eutropha) and should contribute to the clarification of its role as a human pathogen, e.g., in cystic fibrosis.
species identifications by PCR were performed in duplicate, each time starting with new cultures.
The amplification products were checked by agarose gel electrophoresis and purified of salt and excess primers by using a PCR purification kit from Qiagen.
Agarose gel electrophoresis. Agarose gel electrophoresis was performed as described previously (2) .
Sequence determination. The amplified rDNA was sequenced as described previously (14) . The two DNA strands were sequenced from different PCR products. A 373A DNA Sequencer (Applied Biosystems) was used, and the protocol of the manufacturer for dye terminator reactions was followed.
Analysis of the sequence data. The nucleotide sequences were aligned with reference rDNA sequences provided in the noncommercial software program package ARB (beta-version 2.4). Secondary-structure analysis was done as described by Ludwig et al. (15) .
Nucleotide sequence accession number. The 23S rDNA sequence of B. gladioli DSM 4285 has been deposited in the EMBL database under accession no. Y17182.
16S and 23S rDNA sequences. 16S rDNA sequences of three B. cepacia strains (9, 15, 16) and two B. gladioli strains (13, 27) had already been published. The 23S rDNA of B. cepacia DSM 50181 (X16368) was also available (11) . No 23S rDNA sequence of B. gladioli had yet been described. We therefore determined the 23S rDNA gene sequence of B. gladioli DSM 4285 (2,882 bp). Partial 16S and 23S rDNA sequences of additional strains (four of B. gladioli and two of B. cepacia) from various sources were also determined ( Fig. 1 and 2) .
Analysis of 16S and 23S rDNAs for signature sequences. The prerequisite for discrimination of species by their S rDNAs are interspecies sequence deviations and their consistency among different strains of one species. There should be no or only low intraspecies sequence variability within the signature sequence section. Both conditions were checked by multiple sequence alignment of the hypervariable regions within the 16S and 23S rDNAs. Interspecies sequence deviations were identified in the helix 18a/18b region of the 16S rDNA. Within a region of the appropriate length for a primer (e.g., 18-mer), no intraspecies variability was detected among the seven B. gladioli strains and only one variable position (472) was found in B. cepacia. In the helix 37a/37b region, B. cepacia presents both consistent interspecies deviations (at four positions) and only minor intraspecies sequence variations. Therefore, this region might be exploited for a signature sequence specific for B. cepacia. Within the 23S rDNA hypervariable regions, only the helix 45a/b section carries useful interspecies differences (for B. gladioli at five positions and for B. cepacia at six positions) without major intraspecies variability (at two positions each for B. gladioli and B. cepacia). Altogether, five candidates for species-specific sequences were identified. They are characterized in Table 1 .
Selection of primers for PCR. The aim was to establish a procedure which allows discrimination of strains of both species by a single PCR. Thus, the selection of primers was guided towards PCR products of different lengths for either species. Therefore, a constant sense primer (annealing to a DNA target common to both species) was paired with a primer specific for either B. gladioli or B. cepacia or B. cepacia plus B. multivorans that, however, anneals at a distance different from that of the sense primer ( Table 2 ). The PCR products obtained with different sets of primers are shown in Fig. 3 , which demonstrates the efficacy and specificity of the proposed primers both alone and in combination.
Evaluation of primer specificity. The abilities of the primers to initiate the synthesis of species-specific PCR products were evaluated with strains of various Burkholderia and Ralstonia species from type culture collections (Table 3) . Either no PCR products or amplification products of the expected sizes were found (Table 3) . Furthermore, three strains each of P. aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter baumannii were investigated for cross-reactivity with the selected primers. No PCR product was detected with these strains (data not shown).
Comparison of species identifications by PCR and by biochemical tests of clinical isolates.
A number of Burkholderia strains isolated from cystic fibrosis patients at various centers in Europe and Canada were identified to the species level by biochemical reactions as proposed by Vandamme et al. (24) . Their phenotypic identification was confirmed by the PCR procedure (Table 3) . However, three strains sent to our laboratory as B. cepacia were found to be B. gladioli by PCR.
B. gladioli has been associated with lung infections in humans with an impaired host defense, e.g., in chronic granulomatous disease (10, 21) , where a genetic defect causes ineffective killing mainly of pathogens producing catalase (such as B. gladioli). B. gladioli was first isolated from sputa of patients suffering from cystic fibrosis by Mortensen et al. (19) and Christenson et al. (6) and was then regarded as a commensal. In contrast, Khan et al. (12) described the growth of B. gladioli (without P. aeruginosa) in the sputum of a cystic fibrosis patient before lung transplantation, in the explant, and on postoperative day 40 in abscess drainage fluid, pleural fluid, and two sets of blood cultures. The patient died 6 months after lung transplantation. Those authors considered B. gladioli to be a pathogen of cystic fibrosis patients who undergo lung transplantation. Wilsher et al. (26) All six patients died of respiratory failure between 1 and 20 months after acquisition of B. gladioli, one from fulminant B. gladioli septicemia. This is the first report of B. gladioli septicemia in a patient with cystic fibrosis. Simpson et al. (22) and Baxter et al. (3) described strains isolated from cystic fibrosis patients which could not unambiguously be identified either as B. cepacia or B. gladioli and therefore were supposed possibly to represent intermediates between the two species. These reports demonstrate the controversy about the role of B. gladioli in the clinical course of cystic fibrosis. This is partly due to a deficit of procedures for unequivocal identification of B. gladioli in routine diagnostic laboratories (9, 25) . Baxter et al. (3) reported that none of nine tests selected from the literature for their potential to differentiate between B. gladioli and B. cepacia produced clear-cut results. Furthermore, 7 of the 32 strains investigated possessed about equal characteristics of both species and were therefore regarded as hybrids. The API 20NE kit falsely identifies B. gladioli as B. cepacia. More reliable identification is achievable by analysis of the fatty acid methyl ester profile (3, 7, 22, 23) . In addition, DNA-DNA hybridization was used to differentiate B. gladioli and B. cepacia (1, 6, 25) . These procedures are, however, usually not established in laboratories for routine diagnostic use.
Our approach for discrimination of B. gladioli and B. cepacia is based upon the genetic diversity of S rDNAs between the two species. The primers designed for distinction between B. gladioli and B. cepacia were selected to generate amplicons of clearly different sizes for the two species and for not crossreacting with other Burkholderia (B. pseudomallei and B. mallei) and Ralstonia (Ralstonia pickettii and Ralstonia eutropha) species (Table 3) . Therefore, a PCR-based procedure for specific identification of B. gladioli was established. Its main utility in clinical laboratories is more rapid identification of strains grown on selective media (5 h versus up to 5 days) and, furthermore, clarification of uncertain species identification by biochemical reactions. The PCR technique has been established in the majority of clinical laboratories, so there is adequate equipment and technical know-how to allow the use of this procedure in a reliable way.
The procedure is inadequate for discrimination of B. cepacia genomovars I, III, and IV. It should, however, contribute to the clarification of the role of B. gladioli and other Burkholderia species in cystic fibrosis.
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